Peter Gluckman
29Patents
7h-index
34Co-inventors
69Inventor score
Filing activity: Sep 26, 1991 → Nov 12, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5714460A | IFG-1 to improve neural outcome | Human Necessities | 54 | Expired |
| US6187906A | Methods to improve neural outcome | Human Necessities | 31 | Expired |
| US5434134A | Use of human IGF-1 to treat cardiac disorders | Human Necessities | 18 | Expired |
| US7714020B2 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | Human Necessities | 13 | Active |
| US5861373A | IGF-1 to improve the neural condition | Human Necessities | 12 | Expired |
| US5534493A | Use of growth factor IGF-I or IGF-II | Human Necessities | 9 | Expired |
| US5420111A | IGF-1 and related compounds in pregnancy | Human Necessities | 7 | Expired |
| US6365573B1 | Regulation of neural enzymes | Human Necessities | 7 | Expired |
| US7605177B2 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | Human Necessities | 7 | Expired |
| US8637567B2 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid | Human Necessities | 6 | Active |
| US6034059A | Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients | Human Necessities | 5 | Expired |
| US5482926A | Growth factor IGF-Il | Human Necessities | 3 | Expired |
| US6617311B1 | Regulation of tyrosine hydroxylase | Human Necessities | 2 | Expired |
| US6780848B2 | Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease | Human Necessities | 2 | Expired |
| US6204240A | TGF-.beta.1 to improve neural outcome | Human Necessities | 2 | Expired |
| US5922673A | Method of treating hypertension in pregnant mammals | Human Necessities | 1 | Expired |
| US7304029B1 | Neuroprotective effect of growth hormone | Human Necessities | 1 | Expired |
| US5710127A | Use of growth factor IGF-I and/or IGF-II | Human Necessities | 1 | Expired |
| US5858966A | Fetal growth | Human Necessities | 1 | Expired |
| US5783560A | Use of human growth hormone for preoperative administration | Human Necessities | 0 | Expired |
| USRE43982E1 | IGF-1 to improve neural outcome | General | 0 | Expired |
| US10517891B2 | Maternal vitamin B12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers | Human Necessities | 0 | Active |
| US7112570B2 | GPE analogs | Human Necessities | 0 | Expired |
| US6812208B2 | Methods to improve neural outcome | Human Necessities | 0 | Expired |
| US9980950B2 | Maternal vitamin B6 administration for the prevention of increased adiposity, overweight or obesity in the offspring | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.